SLXNNasdaq

Silexion Therapeutics Corp

Healthcare·Oncology·Phase 2·Jerusalem, Israel
Oncology

Silexion Therapeutics Corp (SLXN): 2 pipeline candidates · ~2 mo cash runway. Updated within the last hour.

4.6/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway0.7

2.4 months

Financial Health4.7

D/E 14.81 · 3% dilution

Pipeline Maturity8.5

Lead: Phase 2/Phase 3

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider Signal4.3

0 buys · 1 sell (180d)

A transparent, data-derived signal for Silexion Therapeutics Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$2.7M

Cash

$2.5M

Quarterly Burn

$3.6M

Runway

2.4 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2026
Today~7 mo out
Catalyst within runway

Pipeline (2 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

4

Total value held

$46K

HolderSharesValue
citadel advisors llc20,926$27K
two sigma securities, llc11,657$15K
montag a & associates inc3,000$4K
jones financial companies lllp26$32
·CEO: Mr. Ilan Hadar M.B.A.

Frequently asked questions

How many drug candidates are in Silexion Therapeutics Corp's pipeline?

Silexion Therapeutics Corp (SLXN) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Silexion Therapeutics Corp's lead drug candidate?

Silexion Therapeutics Corp's most advanced tracked candidate is sig12d-loder (Phase 2) for Non-resectable locally advanced pancreatic cancer (LAPC).

What is Silexion Therapeutics Corp's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Silexion Therapeutics Corp has approximately 2.4 months of cash runway.

What is Silexion Therapeutics Corp's market capitalization?

Silexion Therapeutics Corp's market capitalization is approximately $2.7M.

Who is the CEO of Silexion Therapeutics Corp?

Mr. Ilan Hadar M.B.A. is the chief executive officer of Silexion Therapeutics Corp (SLXN).

Get the full picture on Silexion Therapeutics Corp

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.